Effects of hypothermia on drug disposition, metabolism, and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system.
OBJECTIVE
Therapeutic hypothermia has been shown to decrease neurologic damage in patients experiencing out-of-hospital cardiac arrest. In addition to being treated with hypothermia, critically ill patients are treated with an extensive pharmacotherapeutic regimen. The effects of hypothermia on drug disposition increase the probability for unanticipated toxicity, which could limit its putative benefit. This review examines the effects of therapeutic hypothermia on the disposition, metabolism, and response of drugs commonly used in the intensive care unit, with a focus on the cytochrome P450 enzyme system.


METHODS
A MEDLINE/PubMed search from 1965 to June 2006 was conducted using the search terms hypothermia, drug metabolism, P450, critical care, cardiac arrest, traumatic brain injury, and pharmacokinetics.


METHODS
Twenty-one studies were included in this review. The effects of therapeutic hypothermia on drug disposition include both the effects during cooling and the effects after rewarming on drug metabolism and response. The studies cited in this review demonstrate that the addition of mild to moderate hypothermia decreases the systemic clearance of cytochrome P450 metabolized drugs between approximately 7% and 22% per degree Celsius below 37degreesC during cooling. The addition of hypothermia decreases the potency and efficacy of certain drugs.


CONCLUSIONS
This review provides evidence that the therapeutic index of drugs is narrowed during hypothermia. The magnitude of these alterations indicates that intensivists must be aware of these alterations in order to maximize the therapeutic efficacy of this modality. In addition to increased clinical attention, future research efforts are essential to delineate precise dosing guidelines and mechanisms of the effect of hypothermia on drug disposition and response.
Tortorici
Michael A
MA
University of Pittsburgh School of Pharmacy, Department of Pharmaceutical Sciences, Pittsburgh, PA, USA.
Kochanek
Patrick M
PM
Poloyac
Samuel M
SM
D000777:Anesthetics / Q000378:metabolism; D000927:Anticonvulsants / Q000378:metabolism; D002317:Cardiovascular Agents / Q000378:metabolism; D002753:Chlorzoxazone / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000378:metabolism; D007036:Hypothermia, Induced / Q000009:adverse effects*; D008874:Midazolam / Q000378:metabolism; D009466:Neuromuscular Blocking Agents / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*
D000777:Anesthetics; D000927:Anticonvulsants; D002317:Cardiovascular Agents; D006993:Hypnotics and Sedatives; D009466:Neuromuscular Blocking Agents; D004364:Pharmaceutical Preparations; D003577:Cytochrome P-450 Enzyme System; D002753:Chlorzoxazone; D008874:Midazolam